Evaluation of the humoral response to COVID-19 vaccines in Brazil
Recruiting
- Conditions
- RNA Virus InfectionsAntibody FormationImmunogenicity, VaccineB34.2
- Registration Number
- RBR-33ndb47
- Lead Sponsor
- Fundação Oswaldo Cruz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Men and women aged 18 years and over; A resident of the metropolitan region of Rio de Janeiro or the state of Ceará; Have received at least one dose of ChAdOx1-nCov19 (AstraZeneca-Oxford /Fiocruz) or Coronavac (Butantan) vaccine in the states of Rio de Janeiro or Ceará; Accept to participate in the study by signing the Informed Consent Form.
Exclusion Criteria
Men and women with unavailability to comply with the follow-up schedule
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the spike protein-specific anti-SARS-CoV 2 IgG titer after each vaccination regimen
- Secondary Outcome Measures
Name Time Method Secondary Outcome 1: Describe the time to seroconversion of spike protein-specific anti-SARS-CoV 2 IgG antibodies after vaccination;Secondary Outcome 2: Analyze the cellular immunity after 3, 6 and 9 months of vaccination with the 3rd dose of the vaccine;Secondary Outcome 3: Verify the frequency of adverse events from COVID-19 vaccination;Secondary Outcome 4: Verify the frequency of positive RT-PCR examination, after vaccination and over one year after vaccination 3rd dose of vaccine;Secondary Outcome 5: Verify the time between positive RT-PCR test and 1st, 2nd and/or 3rd dose of vaccination and throughout one year after the 3rd dose of the vaccine;Secondary Outcome 6: Identify the titer of neutralizing antibodies after the 1st, 2nd and 3rd dose of vaccination